Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information
Phone(732) 524-3218
DescriptionVenture capital subsidiary



410 George Street
New Brunswick, NJ, 08901


Vice President Venture Investing
Vice President, Venture Investments
Vice President, Venture Investments
VP, Venture Investments
Vice President
Vice President, Venture Investments
Principal, Venture Investments
Principal, Venture Investments
Show All People


Johnson & Johnson Development Corporation

Johnson & Johnson Development Corporation (JJDC) is the venture capital subsidiary of Johnson & Johnson. JJDC is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, health care trends, and strategic investment opportunities. Unlike traditional venture capital firms, JJDC determines the success of an investment’s performance not only in financial returns, but also in the viability of providing strategic growth options for Johnson & Johnson.

JJDC plays an integral role in the identification of new business opportunities outside of Johnson & Johnson’s traditional portfolio and market presence. JJDC identifies new market opportunities and develops new businesses in emergent health care sectors while also creating support venture investments in alignment with the strategic objectives of Johnson & Johnson operating companies.

Recent Milestones


Company Date Round Size Participants
PowerVision 1/2014Series D$20M6
TopiVert 1/2014Venture Round£4.5M4
Pulmocide 11/2013Series A£17M4
Biocartis 11/2013Series E€30M6
Merus 10/2013Series B€31M5
ReVision Optics 7/2013Private Equity$55M6
CVRx 7/2013Series F$29.6M4
ViaCyte 7/2013Series C$10.6M2
NeuroPace 7/2013Partial Close$18M5
Rodin Therapeutics 6/2013Seed2
Protagonist Therapeutics 6/2013Series B$14M3
Aquinox Pharmaceuticals 4/2013Series C$18M5
Catalyst Biosciences 4/2013Venture Round$5.07M6
Nevro 3/2013Series C$48M9
OptiScan Biomedical 2/2013Private Equity$30.7M4
Genocea Biosciences 10/2012Series C$30M10
Catalyst Biosciences 9/2012Partial Close$13.4M5
Astute Medical 6/2012Series C$40.4M6
PhaseBio Pharmaceuticals 6/2012Series B$23M5
Mitralign 5/2012Series D$35M6
Direct Flow Medical 4/2012Venture Round$284k9
Celladon 2/2012Venture Round$43M6
iScience Interventional 1/2012Partial Close$2.76M6
PowerVision 1/2012Series C$12.5M1
Pronota 1/2012Series C€3.7M7
Biocartis 11/2011Series C€71M3
Nevro 7/2011Venture Round$58M7
Atlas Genetics 7/2011Series B£16.9M5
Spinal Modulation 6/2011Series D$30M8
Astute Medical 3/2011Series B$13M4
23andMe 1/2011Series C$9M1
Zeo 1/2011Series C$12.3M4
Genocea Biosciences 1/2011Series B$35M9
Syntaxin 11/2010Series C$29M7
23andMe 11/2010Series C$22M3
Intio 10/2010Series B$8.1M1
Aquinox Pharmaceuticals 6/2010Series B$25M4
Breathe Technologies 5/2010Series C$23M4
Astute Medical 5/2010Series B$26.5M4
Biocartis 4/2010Series B$41.3M5
PhaseBio Pharmaceuticals 1/2010Series B$25M5
Molecular Partners 12/2009Series B$44.2M5
Spinal Modulation 11/2009Series C$27.4M7
Celladon 11/2009Series C$21.8M3
Sleep Solutions 10/2009Series F$20M6
Direct Flow Medical 10/2009Series C$40M7
Neotract 9/2009Series B$28.1M2
Neurosearch 8/2009Venture Round$14.3M1
Pronota 6/2009Series B$7.36M7
CoAxia 6/2009Series D$21.5M6
iScience Interventional 5/2009Series F$20.5M8
ImaCor 2/2009Series A$5.45M2
Catalyst Biosciences 12/2008Series C$40M7
Biolex Therapeutics 10/2008Series D$60M11
Brainsgate 8/2008Venture Round$27.5M1
Neuron Systems 8/2008Series A$8.96M2
InSound Medical 2/2008Series E$11M3
Syntaxin 10/2007Series B$32M5
PhaseBio Pharmaceuticals 10/2007Series B$6.6M3
Tengion 10/2007Series C$33M9
Molecular Partners 8/2007Series A$15.6M4
ViaCyte 7/2007Series C$25M4
Biolex Therapeutics 5/2007Series C$30M9
CymaBay Therapeutics 4/2007Series D$32M16
Axial Biotech 3/2007Series B$15.3M3
Tengion 6/2006Series B$50M7
ViaCyte 5/2006Venture Round$20M8
Pronota 4/2006Series A$7.8M2
Light Sciences Oncology 12/2005Series A$67M8
Biolex Therapeutics 9/2005Series B$36M6
Tengion 8/2005Series A$39M4
Biolex Therapeutics 1/2005Venture Round$8M1



  1. PowerVision Raises $20M in Series D Funding ( [edit]
  2. TopiVert Raises Follow-on Funding ( [edit]
  3. Pulmocide Raises £17M in Series A Funding ( [edit]
  4. Biocartis Completes €30M Series E Equity Funding ( [edit]
  5. Merus Raises €31M in Series B Financing ( [edit]
  6. ReVision Optics Raises $55M In Equity Financing ( [edit]
  7. CVRx Completes $29.6M Equity Financing ( [edit]
  8. ViaCyte Raises $10.6 Mln ( [edit]
  9. Medical device maker NeuroPace raises $18M of planned $50M ( [edit]
  10. Atlas Venture, Johnson & Johnson Development Seed Rodin Therapeutics ( [edit]
  11. Protagonist Therapeutics Raises $14 Million in Series B Venture Financing ( [edit]
  12. Aquinox Pharmaceuticals Completes US $18 million Series C Financing ( [edit]
  13. VC Funding: Q2 2013 source [edit]
  14. Nevro Raises $48M in Series C Financing ( [edit]
  15. OptiScan Biomedical ( [edit]
  16. Genocea raises $30M to advance herpes vaccine ( [edit]
  17. SEC ( [edit]
  18. Astute Medical Completes $40.4M Series C Financing ( [edit]
  19. PhaseBio Pharmaceuticals Books $23M in Third Tranche of Series B ( [edit]
  20. Mitralign Closes $35M in Series D Financing ( [edit]
  21. VC Funding: Q2 2012 source [edit]
  22. Celladon Closes $43M in Funding ( [edit]
  23. iScience Interventional Raises US$2.8 Million In Venture Financing ( [edit]
  24. PowerVision Receives $12.5M Investment from JJDC in Series C Round ( [edit]
  25. [edit]
  26. Biocartis Completes €71M Series C Equity Funding ( [edit]
  27. Nevro Completes $58M Financing ( [edit]
  28. Atlas Genetics Ltd Completes £16.9 million Series B Financing led by Novartis Venture Funds ( [edit]
  29. Spinal Modulation Secures $30 Million Series D Financing ( [edit]
  30. Astute Medical Completes $13 Million Financing With Existing Stockholders ( [edit]
  31. Johnson & Johnson Leads $9 Million Investment In Personal Genetics Startup 23andMe ( [edit]
  32. Zeo Receives $12.3M Third Financing ( [edit]
  33. Genocea Biosciences Closes $35M Series B Financing Round ( [edit]
  34. VCs inject $29M into Syntaxin, $11.5M into Ceregene ( [edit]
  35. Personal Genetics Startup 23andMe Raises $22 Million More From Google, Others ( [edit]
  36. Johnson & Johnson Backs Intio In $8.1M Series B Round ( [edit]
  37. Aquinox Pharmaceuticals completes US $25 million Series B financing ( [edit]
  38. Breathe Technologies, Inc.: Series C $23M ( [edit]
  39. Astute Medical, Inc.: Series B $26.5M ( [edit]
  40. Biocartis raises €30 million in Series ‘B' financing round ( [edit]
  41. PhaseBio Pharmaceuticals Raises $25M in Series B Funding Round ( [edit]
  42. Swiss Protein Therapy Co. Molecular Partners Pulls In $44M Series B ( [edit]
  43. Spinal Modulation raises $27M to treat spinal pain ( [edit]
  44. Celladon, Inc.: Series C $21.8M ( [edit]
  45. Sleep Solutions, Inc.: Series F $20M ( [edit]
  46. Direct Flow Medical takes $40M for heart valve treatments ( [edit]
  47. SEC ( [edit]
  48. NeuroSearch announces drug discovery and drug development alliance with Janssen Pharmaceutica NV ( [edit]
  49. Pronota announces EUR 4.9 million first close of series B financing ( [edit]
  50. CoAxia, Inc.: Series D $21.5M ( [edit]
  51. iScience Interventional, Inc.: Series F $20.5M ( [edit]
  52. SEC ( [edit]
  53. Catalyst Biosciences Raises $40 Million in Series C Financing ( [edit]
  54. Biolex Therapeutics Completes $60 Million Series D Financing to Accelerate Development of Locteron® in Hepatitis C ( [edit]
  55. BrainsGate raises $27.5m ( [edit]
  56. Equity Help Desk ( [edit]
  57. InSound Medical takes in $11M for “invisible” hearing aids — albeit ones that have been on the shelf for a while ( [edit]
  58. Syntaxin Raises $32M to Advance Development of Novel Drug Pipeline ( [edit]
  59. Phase Bioscience raises $6.6 million ( [edit]
  60. Tengion Closes $33 Million in Series C Funding Deerfield Partners Joins Investor Group as Company Advances Novel Regenerative Medicine Products ( [edit]
  62. Novocell Raises $25 Million ( [edit]
  64. Metabolex ( [edit]
  65. Axial Biotech Announces $15.3 Million Series B Financing ( [edit]
  66. Tengion Inc. Completes $50 Million Series "B" Round Financing led by Bain Capital and Quaker BioVentures will support neo-bladder clinical trials, manufacturing capacity and pipeline development ( [edit]
  67. EDGAR [edit]
  68. Peakadilly announces EUR 6 million first close of series A financing ( [edit]
  69. Light Sciences Oncology Completes Second Closing in $67 Million Financing for Late Stage Development of Litx(TM) and Announces Additional Directors; Investors' Additional $32 Million Completes Offering of Series A Preferred ( [edit]
  71. Tengion Inc. Completes $39 Million Series "A" Round Financing Will Advance Development of Regenerative Medicine Products ( [edit]
  72. EDGAR [edit]
Edit This Page
Last Edited 4/11/14

Revision History RSS Picture


Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API


Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy